Eli Lilly (LLY) said Tuesday it doesn't have any affiliation with Hims & Hers Health (HIMS), adding that its weight-loss drug Zepbound, or tirzepatide, can be prescribed by "any licensed healthcare professional."
Hims & Hers earlier said it was expanding its weight-loss products on its telehealth platform to include generic liraglutide and branded tirzepatide.
Hims & Hers shares were down 4.9% in recent premarket activity Wednesday, while Lilly fell 0.3%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。